Pancreatic cancer survival in central and northern Denmark from 1998 through 2009: a population-based cohort study

Figures & data

Figure 1 Age at diagnosis of pancreatic cancer patients in Central and Northern Denmark 1998–2009 by gender.

Table 1 Cumulative survival and crude and adjusted relative mortality (MRR) (and associated 95% confidence intervals) for pancreatic cancer patients diagnosed in Central and Northern Denmark, 1998–2009

	Year of diagnosis
	1998–2000	2001–2003	2004–2006	2007–2009
Number of cancer patients	607	702	768	891
Median age (years)	72	71	71	71
1-year
Survival	14.8% (12.1%–17.8%)	15.1% (12.6%–17.9%)	17.4% (14.9%–20.2%)	17.7% (15.3%–20.4%)
Relative mortality	1 (reference)	0.98 (0.87–1.10)	0.88 (0.78–0.99)	0.88 (0.79–0.99)
Adjusted relative mortalitya	1 (reference)	0.98 (0.87–1.11)	0.87 (0.77–0.98)	0.86 (0.77–0.96)
3-year
Survival	3.5% (2.2%–5.1%)	3.6% (2.4%–5.1%)	5.1% (3.7%–6.8%)	5.6% (4.2%–7.4%)b
Relative mortality	1 (reference)	0.98 (0.87–1.09)	0.87 (0.78–0.97)	0.87 (0.78–0.96)b
Adjusted relative mortalitya	1 (reference)	0.97 (0.87–1.09)	0.86 (0.77–0.96)	0.84 (0.75–0.93)b
5-year
Survival	2.0% (1.1%–3.3%)	2.1% (1.3%–3.4%)	3.4% (2.3%–4.9%)b	3.8% (2.6%–5.4%)b
Relative mortality	1 (reference)	0.98 (0.88–1.09)	0.87 (0.78–0.97)b	0.86 (0.78–0.96)b
Adjusted relative mortalitya	1 (reference)	0.97 (0.87–1.08)	0.85 (0.76–0.95)b	0.83 (0.75–0.92)b

a Notes: Adjusted for age and gender;

b Predicted values.

Figure 2 Kaplan–Meier survival curves for patients with pancreatic cancer in Central and Northern Denmark regions, 1998–2009.

Table 2A Cumulative survival (and associated 95% confidence intervals) for male pancreatic cancer patients diagnosed in Central and Northern Denmark, 1998–2009

Men age (years)	Year of diagnosis
	1998–2000	2001–2003	2004–2006	2007–2009
15–59
Number of cancer patients	78	82	86	82
1-year survival	24.4% (15.5%–34.3%)	18.3% (10.8%–27.3%)	30.2% (20.9%–40.1%)	24.0% (15.3%–33.7%)
3-year survival	9.0% (3.9%–16.6%)	7.3% (3.0%–14.3%)	10.5% (5.1%–18.0%)	7.7% (3.3%–14.4%)a
5-year survival	7.7% (3.1%–14.9%)	6.1% (2.3%–12.7%)	8.3% (3.7%–15.2%)a	6.1% (2.4%–12.1%)a
60–79
Number of cancer patients	170	225	249	277
1-year survival	11.2% (7.0%–16.4%)	18.2% (13.5%–23.5%)	17.3% (12.9%–22.2%)	20.5% (15.9%–25.6%)
3-year survival	1.8% (0.5%–4.7%)	2.7% (1.1%–5.4%)	5.6% (3.2%–9.0%)	7.0% (4.2%–10.7%)a
5-year survival	0.6% (0.1%–3.0%)	0.4% (0.0%–2.3%)	3.3% (1.5%–6.2%)a	4.1% (1.9%–7.6%)a
80+
Number of cancer patients	45	50	60	63
1-year survival	8.9% (2.8%–19.3%)	6.0% (1.6%–14.9%)	8.3% (3.1%–17.0%)	14.3% (7.0%–24.0%)
3-year survival	0%	0%	3.3% (0.6%–10.2%)	3.5% (0.7%–10.3%)a
5-year survival	0%	0%	–	–

a Note: Predicted values.

Table 2B Cumulative survival (and associated 95% confidence intervals) for female pancreatic cancer patients diagnosed in Central and Northern Denmark, 1998–2009

Women age (years)	Year of diagnosis
	1998–2000	2001–2003	2004–2006	2007–2009
15–59
Number of cancer patients	63	66	57	57
1-year survival	25.4% (15.5%–36.6%)	19.7% (11.2%–30.0%)	22.8% (13.0%–34.3%)	27.5% (16.4%–39.9%)
3-year survival	7.9% (2.9%–16.2%)	4.5% (1.2%–11.5%)	10.5% (4.3%–20.0%)	8.2% (2.1%–20.0%)a
5-year survival	6.3% (2.0%–14.2%)	–	8.8% (3.3%–17.9%)a	6.6% (1.5%–17.2%)a
60–79
Number of cancer patients	170	199	218	276
1-year survival	14.1% (9.4%–19.8%)	13.1% (8.8%–18.1%)	17.9% (13.1%–23.3%)	16.4% (12.2%–21.1%)
3-year survival	2.9% (1.1%–6.3%)	3.5% (1.6%–6.8%)	3.2% (1.4%–6.2%)	6.2% (3.6%–9.7%)a
5-year survival	0%	3.0% (1.2%–6.1%)	1.8% (0.6%–4.3%)a	3.6% (1.5%–7.3%)a
80+
Number of cancer patients	81	80	98	136
1-year survival	9.9% (4.6%–17.5%)	10.0% (4.7%–17.7%)	8.2% (3.8%–14.6%)	8.6% (4.6%–14.1%)
3-year survival	1.2% (0.1%–6.0%)	3.8% (1.0%–9.6%)	1.0% (0.1%–5.0%)	0.9% (0.1%–4.3%)a
5-year survival	–	0%	–	–

a Note: Predicted values.

Table 3 30-day mortality and relative mortality (and associated 95% confidence intervals) among pancreatic cancer patients diagnosed in Central and Northern Denmark, 1998–2009

	Year of surgery
	1998–2000	2001–2003	2004–2006	2007–2009
Number of cancer patients	41	44	39	52
Median age (years)	61	59	63	65
30-day mortality	12.2% (5.3%–26.8%)	6.8% (2.3%–19.7%)	5.1% (1.3%–19.0%)	5.8% (1.9%–16.8%)
30-day relative mortality	1 (reference)	0.53 (0.13–2.20)	0.41 (0.08–2.10)	0.45 (0.11–1.88)
30-day relative mortalitya	1 (reference)	0.59 (0.14–2.51)	0.37 (0.07–1.98)	0.38 (0.09–1.63)

a Note: Adjusted for age and gender.